⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30179852 | 1.00 | — | — | |
| SCHEMBL2267813 | 0.79 | — | — | |
| SCHEMBL29427163 | 0.79 | — | — | |
| SCHEMBL29754963 | 0.75 | — | — | |
| SCHEMBL78699 | 0.75 | — | — | |
| SCHEMBL9575829 | 0.75 | — | — | |
| SCHEMBL29455233 | 0.75 | — | — | |
| SCHEMBL218997 | 0.74 | — | — | |
| SCHEMBL1129186 | 0.72 | — | — | |
| SCHEMBL14371942 | 0.72 | TGM2 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 397 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119775225-B | Preparation method and application of pure organic X-ray scintillator material | 厦门大学 | 2025-06-13 | — | — | CN | claimed |
| CN-117885313-B | Preparation method of PE (polyethylene) winding film with strong stretchability | 惠州易捷新材料科技有限公司 | 2025-05-23 | — | — | CN | claimed |
| CN-119775225-A | Preparation method and application of pure organic X-ray scintillator material | 厦门大学 | 2025-04-08 | — | — | CN | claimed |
| CN-117885313-A | Preparation method of PE (polyethylene) winding film with strong stretchability | 佛山市顺捷包装材料有限公司 | 2024-04-16 | — | — | CN | claimed |
| CN-115304633-B | Heavy atom-free photodynamic photosensitizer and preparation method and application thereof | 山西大学 | 2023-12-26 | — | — | CN | claimed |
| CN-115304633-A | Heavy atom-free photodynamic photosensitizer and preparation method and application thereof | 山西大学 | 2022-11-08 | — | — | CN | claimed |
| US-20260132121-A1 | INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF | ODYSSEY THERAPEUTICS INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12624018-B1 | Inhibitors of RIPK2 and medical uses thereof | ODYSSEY THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260053393-A1 | NEAR-IR GLUCOSE SENSORS | PROFUSA INC (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4482579-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO INC (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4051667-B1 | HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS | LILAC THERAPEUTICS INC (US) | 2026-01-28 | — | — | EP | disclosed |
| EP-4676476-A1 | INHIBITORS OF TDP-43 AND TAU AGGREGATION | Aquinnah Pharmaceuticals, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| US-12509415-B2 | Compounds, liquid compositions including compounds, and electroluminescent devices | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2025-12-30 | — | — | US | disclosed |
| EP-1181017-A1 | METALLOPROTEASE INHIBITORS | Pfizer Limited (GB) | 2002-02-27 | — | — | EP | disclosed |
| WO-2001049309-A2 | COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE | PFIZER LIMITED (GB) | 2001-07-12 | — | — | WO | disclosed |
| WO-2001038303-A2 | VITAMIN D ANALOGUES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2001-05-31 | — | — | WO | disclosed |
| CN-1281433-A | Hydroxamic acid derivatives as matrix metalloproteinase (MMP) inhibitors | PFIZER LTD (US) | 2001-01-24 | — | — | CN | disclosed |
| WO-2000074681-A1 | METALLOPROTEASE INHIBITORS | PFIZER LIMITED (GB) | 2000-12-14 | — | — | WO | disclosed |
| EP-1036062-A1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | Pfizer Limited (GB) | 2000-09-20 | — | — | EP | disclosed |
| WO-1999029667-A1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | PFIZER LIMITED (GB) | 1999-06-17 | — | — | WO | disclosed |